Brazil Cannabis Cultivation Compliance: ANVISA RDC 1.013 Working Guide

How does Brazil’s new ANVISA cultivation framework actually work, and what does AE compliance look like before 4 August 2026?

Brazil ANVISA cannabis cultivation compliance is no longer hypothetical. As of 3 February 2026, ANVISA has published a five-resolution framework (RDC 1.011 through RDC 1.015) that legalises domestic medicinal cannabis production for the first time, with the cultivation rules taking effect on 4 August 2026. This guide walks operators through the Autorização Especial (AE) application, the batch traceability standard in Article 15, the four-ministry oversight committee, and the practical compliance steps every applicant needs in place before the deadline.

The framework was not voluntary policy. It was published to comply with a unanimous November 2024 Superior Tribunal de Justiça (STJ) decision that ordered ANVISA to regulate domestic medicinal cannabis production within a fixed deadline. Operators evaluating Brazil entry, AE applicants moving through the petition process, and association cultivators preparing for the judicial transition all share the same calendar now. This pillar consolidates what the resolutions require, where the source PDF circulating in industry channels gets the detail wrong, and how a cultivator can be audit-ready on day one.

What You’ll Learn

• How the RDC 1.011 to RDC 1.015 framework fits together, and which resolution governs which activity
• What an AE petition under RDC 1.013 requires, plus the correct one-year validity rule under RDC 16/2014
• The Article 15 batch traceability standard and Article 16 per-lot THC analysis obligation
• Why the 0.3% cultivation cap and the 0.2% scheduling cutoff are two different numbers (a common operator trap)
• The 5 August 2027 transition path for habeas-corpus cultivators and patient associations
• A practical readiness checklist, including market context (R$953M, 873,000+ patients, 24.6% CAGR per Cognitive Market Research)

Why Does Brazil ANVISA Cannabis Cultivation Compliance Start Now?

Brazil ANVISA cannabis cultivation compliance is judicially compelled, not voluntary. In November 2024, the Superior Tribunal de Justiça (STJ) issued a unanimous decision ordering the agency to regulate domestic medicinal cannabis production within a fixed deadline. ANVISA’s official announcement on 3 February 2026 explicitly referenced the obligation to comply with that ruling. This matters for operators because it changes the political risk profile of the rules: this is not a discretionary framework that ANVISA can quietly walk back. It is a court-mandated response, and the timelines built into the resolutions exist because the STJ said so.

The agency published five resolutions on the same day (3 February 2026), each covering a distinct activity. Read together, they replace the patchwork of judicial habeas-corpus orders, RDC 327/2019 product authorisations, and import-only supply chains that defined Brazilian cannabis up to that point.

The Five Resolutions at a Glance

For Brazil ANVISA cannabis cultivation compliance specifically, three of the five resolutions activate on the same day, 4 August 2026. RDC 1.011 has been in force since the day of publication, which means cannabis scheduling under Portaria 344 has already shifted. RDC 1.015 came into force on 4 May 2026, giving manufacturers and prescribers three months of overlap before the cultivation rules join them. RDC 1.014 deserves a specific note: it is a regulatory sandbox, not a clinical research framework. The version of the checklist circulating in industry channels mislabels 1.014 as clinical research, but that scope sits under RDC 1.012. Sandbox status under 1.014 is designed for small-scale and association activity that does not fit cleanly into the commercial commercialised AE model.

Twin Thresholds: 0.3% Cultivation Cap vs 0.2% Scheduling Cutoff

The most frequent point of operator confusion is the existence of two THC thresholds that do different jobs. RDC 1.013 permits domestic cultivation of medicinal cannabis at THC at or below 0.3%, dry weight. That number is the cultivation ceiling. Cross above it, and the cultivation falls outside the new framework entirely (RDC 1.012 covers research cultivation above 0.3%, and Article 27 of RDC 1.013 carves out the Portaria 344 prohibition on the rest).

RDC 1.011 sets a different number, 0.2%, for a different purpose: scheduling under Portaria 344/1998. Cannabis with THC above 0.2% is classified on List A3 and dispensed against a yellow controlled-substance prescription. Cannabis at or below 0.2% sits on List B1 and is dispensed against a blue prescription. The 0.2% line is a controlled-substance classification line that governs what prescription form a pharmacist uses, not what a cultivator may grow.

Why does this matter for cultivators? Because everything cultivated under RDC 1.013 will be classified on List A3 (yellow receipt) if THC sits between 0.2% and 0.3%, and on List B1 (blue receipt) if it stays at or below 0.2%. Both are legal to cultivate. Both are legal to manufacture into products under RDC 1.015. But the receipting, dispensing, and patient-side documentation differ. Operators planning their crop genetics around this twin-threshold gap need both compliance pathways modelled in their records before harvest one.

Effective-Date Calendar

Market Context: Why Brazil Matters for International Cultivators

Brazil is now Latin America’s largest medicinal cannabis market by every measurable indicator. The 2025 market reached R$953 million (approximately US$187 million), per the Kaya Mind 2025 Yearbook. Registered patients passed 873,000 by November 2025, up from 672,000 a year earlier, a 56% year-over-year increase. Revenue grew 22% over the same period (Kaya Mind), while Cognitive Market Research projects a 24.6% compound annual growth rate through 2030. Forty-nine ANVISA-registered medicinal cannabis products are currently on market, and 2,180 cannabis-based products are available across roughly 80% of Brazilian municipalities (Kaya Mind).

Up to 4 August 2026, every gram of medicinal cannabis raw material sold in Brazil had to be imported under an AE for imported raw material (RDC 327/2019) or grown under a court-ordered habeas-corpus exception. Domestic commercial cultivation was simply not legal. The five-resolution framework changes that economics overnight. For international LPs evaluating a Brazil entry, the framework also creates a clear constraint: cultivation export remains prohibited under Article 9 of RDC 1.013. Brazilian cultivation can supply Brazilian manufacturing only. Operators planning a hub-and-export model need to model that constraint into the business case before they file their AE petition.

Get the Complete Brazil ANVISA Compliance Checklist

Download the full 9-page working guide (Portuguese), including AE petition documents, Article 15 traceability requirements, BPA/GAP record-keeping, and the August 2026 readiness checklist.

Download Free Guide

What Does an AE Petition Require Under RDC 1.013?

Every commercial cultivator under RDC 1.013 needs an Autorização Especial (AE) granted by ANVISA before any plant goes in the ground after 4 August 2026. Article 3 establishes the AE requirement. Article 4 delegates the petition criteria to RDC 16/2014, with six additional documents specific to cultivation: geographic coordinates of the cultivation site, photographs of the area, a yield estimate, evidence of propagation-material origin, the operator’s organisational chart (organograma), and an environmental monitoring plan.

The AE petition is filed in parallel with separate requirements from MAPA (Ministério da Agricultura e Pecuária) for the genetic origin of the propagation material, and with Article 12 acknowledging MAPA’s role in regulating the seeds and plant material themselves. Inspections and ongoing oversight run through a four-ministry coordination committee: ANVISA, the Ministry of Justice, the Ministry of Health, and MAPA. Operators must expect inspections from any of the four during the AE term, with ANVISA leading sanitary inspections and MAPA leading agronomic inspections.

Why AE Validity Is One Year, Not Five (The PDF Got This Wrong)

This is the single most important correction in this guide. Industry copies of the checklist (including the Portuguese PDF circulating since February 2026) describe the cultivation AE as valid for five years and renewable. That is incorrect. The AE for cultivation under RDC 1.013 is valid for one year from the date the initial grant is published in the DOU, and it must be renewed annually.

The five-year figure belongs to a different regime: the Autorização Sanitária for finished cannabis products under RDC 327/2019 (now RDC 1.015/2026). The cultivation AE is governed by RDC 16/2014, the foundational resolution covering AFEs and AEs for controlled-substance activities. Article 4 of RDC 1.013 explicitly defers cultivation AE criteria to RDC 16/2014, and Article 19 of RDC 16/2014 lists “the cultivation of plants that may originate substances subject to special control” among the activities subject to annual renewal.

Article 20 of RDC 16/2014 sets the renewal window: the petition must be filed between 60 and 180 days before the one-year anniversary. File too late and the AE lapses (caduca) on its own. File on time, and if ANVISA does not decide before the expiration date, the AE auto-renews. That timing matters operationally: cultivators need a renewal docket queued at roughly six months into each annual cycle, not at month eleven. Internal compliance calendars built on the wrong (five-year) assumption will miss the first annual renewal entirely.

Article 15 Batch Traceability: The Compliance Backbone

Article 15 of RDC 1.013 establishes the traceability standard that defines what audit-ready Brazil ANVISA cannabis cultivation compliance looks like in practice. The verbatim text is short and prescriptive:

In English: the operator must implement a traceability procedure that ensures identification of the plant species at the cultivation site, allowing, at a minimum, identification by lot number of the cultivation stage, the start date of the respective stage, the variety, and the quantity of plants. Five required fields per lot, at every cultivation stage. That is the floor, not the ceiling.

Article 16 builds on the lot foundation by mandating per-lot laboratory THC analysis: “O estabelecimento deve realizar a análise laboratorial do teor de THC em cada lote da droga vegetal obtida a partir do cultivo.” Every harvested lot must carry a documented THC test result linked to the lot number established under Article 15. Operators in the 0.2% to 0.3% band especially need this discipline because the lab result also determines whether each lot is dispensed against a yellow (List A3) or blue (List B1) receipt.

Chapter IV of RDC 1.013 (Articles 13 through 21) extends the traceability backbone across documentation retention (Article 13), genetic-origin records per acquisition (Article 14), environmental escape prevention (Article 17), destruction of above-0.3% material with 48-hour notification (Article 18), and quarterly plus annual production-estimate reports to ANVISA (Article 19). For software, the practical implication is that a seed-to-sale system must carry lot ID through cultivation stage transitions, variety records, plant counts at each stage, lab results per lot, and a destruction audit trail, all in a form ANVISA can export on demand.

Boas Práticas Agrícolas (BPA/GAP) Record-Keeping

Article 26 of RDC 1.013 cross-references “outras regulamentações aplicáveis”, which in practical terms folds in IN 130/2022 (Good Manufacturing Practices for plant-based medicines), WHO guidance on Good Agricultural and Collection Practices (GACP), and MAPA’s separate agronomic management requirements. Together these define Boas Práticas Agrícolas (BPA/GAP) for medicinal cannabis: documented standard operating procedures, environmental monitoring (temperature, humidity, light), pest and disease management with full input-application logs, irrigation records, personnel training and access controls, post-harvest handling protocols, and equipment calibration records.

None of this is novel for an operator coming from EU-GMP or Health Canada. The mechanics are familiar. What is specific to Brazil is the audit format: BPA records must be available on-site for the four-ministry committee to review during inspection, retained for the minimum period set by Portaria 344/1998, and structured so that any lot can be reconstructed end-to-end from propagation material acquisition through destruction or transfer.

The Habeas-Corpus and Association Transition Path

Before 4 August 2026, Brazilian domestic cultivation operated only through judicial habeas-corpus or salvo-conduto orders, with patient associations (APEPI and similar organisations) cultivating under court protection rather than regulatory permission. Article 28 of RDC 1.013 gives those operators a transition window: cultivators authorised by judicial decision before the resolution’s publication have until 5 August 2027 to complete the migration to an AE under RDC 1.013.

This is a one-year overlap window on top of the 4 August 2026 effective date. Practically, judicial cultivators have 18 months from the publication of RDC 1.013 (3 February 2026) to file an AE petition, receive a grant, and bring their existing operation into compliance with the new framework. After 5 August 2027, habeas-corpus authority alone is no longer sufficient. Operators in this category should treat the AE petition as a transition exercise rather than a fresh entry: existing operational records, plant inventories, and genetic-origin documentation should carry forward into the petition where possible. The RDC 1.014 sandbox provides a parallel route for associations whose scale or model does not fit the commercial AE channel.

The Practical Readiness Checklist

Anchoring the work backward from 4 August 2026, an applicant building toward day-one Brazil ANVISA cannabis cultivation compliance needs the following documented and tested:

Documentation track

• Geographic coordinates of the cultivation site (with photographs)
• Yield estimate (BSPO, Brazilian Standard Production Estimate)
• Propagation-material origin documentation, including MAPA-aligned genetic origin
• Organisational chart (organograma) showing roles, responsibilities, and lines of authority
• Environmental monitoring plan (temperature, humidity, light, security)
• Standard operating procedures for every cultivation stage

Operational track

• Lot-numbering system aligned to Article 15 (stage, start date, variety, plant count)
• Per-lot laboratory THC analysis pipeline ready under Article 16
• Destruction protocol for any above-0.3% material with 48-hour ANVISA notification path
• Quarterly and annual production-estimate (BSPO) reporting workflow
• Renewal calendar pre-loaded with the 60-180-day petition window per RDC 16/2014 Art. 20

Inter-ministry coordination track

• MAPA dossier on propagation material and agronomic management (Art. 12)
• ANVISA AE petition under RDC 16/2014 plus the six Article 4 cultivation-specific documents
• Ministry of Justice security plan (controlled-substance handling, site security, transport)
• Ministry of Health alignment on patient-facing dispensation pathway through RDC 1.015 partners

Operators should also expect inspections from any of the four ministries during the AE term. A single inspection-ready document package, exportable on demand, is more valuable than four separate filing cabinets.

Get the Complete Brazil ANVISA Compliance Checklist

Download the working guide for AE applicants, judicial-transition cultivators, and international LPs entering Brazil. Includes the full Article 15 traceability map, Article 16 lab analysis workflow, and the 4 August 2026 readiness checklist.

Download Free Guide

Frequently Asked Questions

Brazil Cannabis Cultivation Compliance, Solved.

GrowerIQ’s seed-to-sale platform was built for Brazil ANVISA cannabis cultivation compliance. It carries Article 15 lot identification, Article 16 per-lot THC analysis, BPA/GAP records, and the four-ministry document package every AE applicant needs. See how operators ready themselves for 4 August 2026 with one inspection-ready export, not four filing cabinets.

REQUEST DEMO